Felbinac, an active pharmaceutical ingredient (API) used clinically for the treatment\nof osteoarthritis, has poor solubility. Felbinac cataplasm product design was investigated using\nrheological and mechanical analyses. Experiments using a response surface methodology based\non Boxââ?¬â??Behnken design (BBD) incorporated three independent variables: the proportions of\npartially neutralized polyacrylate (NP800), dihydroxyaluminum aminoacetate (DAAA), and felbinac.\nStatistically significant quadratic models obtained using BBD demonstrated optimal NP-800,\nDAAA, and felbinac cataplasm proportions of 4.78ââ?¬â??5.75%, 0.30ââ?¬â??0.59%, and 0.70ââ?¬â??0.90%, respectively.\nFelbinac cataplasms exhibited ââ?¬Å?gel-likeââ?¬Â mechanical property with predominantly elastic behavior.\nRheological studies correlated increasing NP-800 and DAAA concentrations with increased complex\nmodulus (G*) values that were inversely related to peeling strength. Frequency sweep and creep tests\nrevealed decreasing tan Ã?¸ values with increasing NP-800 and DAAA concentrations. Gââ?¬â?¢ and Gââ?¬Â values\nwere higher for higher NP-800 and DAAA levels, although Gââ?¬Â values decreased with increasing\nDAAA concentration. Response surface methodology was applied to develop mathematical models.\nVariance analysis showed that the quadratic model effectively predicted felbinac and matrix material\ninteractions, with two verification samples upholding model predictions. Relative errors between\npredicted and measured G* values were 3.28% and 1.10% and for peeling strength were 1.24% and\n5.59%, respectively. In conclusion, rheological and mechanical analyses of felbinac cataplasms using\nBBD permits optimization of cataplasms as topical drug delivery vehicles.
Loading....